Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
5.5.2021 13:30:00 EEST | Business Wire | Press release
Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that the first patient has been treated in the company’s Phase 2/3 pivotal trial evaluating ADG20 for the prevention of COVID-19, known as the EVADE trial. Trial initiation is supported by positive preliminary data from the company’s ongoing Phase 1 trial in healthy volunteers. EVADE will be conducted globally at more than 100 sites, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, and will evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.
The initiation of the EVADE trial is supported by blinded data from Adagio’s ongoing first-in-human, randomized, placebo-controlled Phase 1 clinical trial. The Phase 1 trial was designed to evaluate the safety, tolerability, pharmacokinetics and serum SARS-CoV-2 neutralizing antibody levels of various ADG20 dose regimens. Preliminary data demonstrate that a single intramuscular injection of ADG20 is well tolerated at doses up to 600 mg, and the initial pharmacokinetic profile support a prolonged serum half-life, which has the potential to afford up to 12 months of protection against COVID-19. In addition, initial ADG20 serum virus neutralizing activity against authentic SARS-CoV-2 is similar to peak serum neutralizing antibody titers reported for mRNA COVID-19 vaccine recipients.
“We are pleased with the strength of our initial clinical data and with the initiation of the EVADE trial to assess the efficacy of ADG20 in two key settings for the prevention of symptomatic COVID-19,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “Based on its potent and broad activity and extended duration of effect in preclinical models, we believe that ADG20 has the potential to provide both rapid protection in the face of a known, recent exposure to an individual with SARS-CoV-2 infection as well as durable protection over several months, including for individuals who are unlikely to have a sufficiently protective immune response to vaccines. We appreciate the enthusiasm expressed by our investigators and their support in advancing this differentiated antibody therapy.”
“COVID-19 continues to be a significant health crisis, and with the recurring emergence of new variants across the globe, we believe a broadly neutralizing therapy that could be given for both treatment and prevention will be necessary,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio.
The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. After evaluation of data from the first 200 adult participants in the Phase 2 portion of the trial, enrollment may be opened to adolescents and pregnant women in Phase 3. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit clinicaltrials.gov.
The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).
About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.
About Adagio Therapeutics
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005365/en/
Contact information
Media:
Dan Budwick, 1AB
Dan@1abmedia.com
Investors:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Rises in France’s Top 85 Technology Services Ranking, Recording Significant Revenue Growth in the Market17.11.2026 08:30:00 EET | Press release
Global technology corporation FPT has ranked 85th among France’s digital services and technology consulting companies in the KPMG France and Numeum’s 2026 ranking, climbing 20 places year-on-year. The advancement follows approximately 50% revenue growth in France, reflecting the company’s expanding business scale and strengthening competitive position in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116291751/en/ The annual ranking covers 175 digital services and engineering and technology consulting companies based on their 2025 revenue generated in France. Published alongside the ranking, KPMG and Numeum’s Grand Angle ESN & ICT study highlights a broader industry shift, with generative and agentic AI emerging as major forces reshaping business models across the French technology services market. FPT’s growth in France has been built on long-standing relationships with major enterprises and its expanding rol
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 03:30:00 EET | Press release
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for the first time reflects both the strength of India's technology ecosystem and the growing role its enterprises play in shaping global supply chai
Povofortay ® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 23:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2 Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 23:00:00 EET | Press release
Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise workflows and move AI agents from pilots into everyday work. Mr. Bhatt will also continue as Chief Technology Officer of Moody’s Ratin
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 23:00:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platform is well suited to a terminal that must run for years without maintenance. “As optical links and onboard processing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
